Query String: OMEPRAZOLE
BDBM586110 USRE49340, Rank 1 5-O-Desmethyl- Omeprazole (RS-D7)
Omeprazole Prilosec Antra BDBM50103597 H 168/68 CHEBI:77260 Losec H-168/68
Omeprazole sulfone CHEMBL1344 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfonyl)-1H-benzoimidazole BDBM50139805
5-methoxy-2-(2-(4-methoxy-3,5-dimethylpyridin-2-yl)ethylsulfinyl)-1H-benzo[d]imidazole cid_4594 2-(3-methoxy-2,4-dimethylbenzylsulfinyl)-6-methoxy-1H-benzo[d]imidazole OMEPRAZOLE 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole BDBM50241343 (RS)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) methylsulfinyl)-1H-benzo[d]imidazole CHEMBL1503 Prilosec 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole (omeprazole) (omeprazole)5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole ESOMEPRAZOLE SODIUM 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole(omeprazole) 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole H-168/68 Omeprazole (OMP)
Omeprazole sulfide Ufiprazole 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethylsulfanyl)-1H-benzoimidazole BDBM50240509 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylthio)-1H-benzo[d]imidazole CHEMBL892
- Pauli-Magnus, C; Rekersbrink, S; Klotz, U; Fromm, MF Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 364: 551-7 (2001)
- Carlton, DL; Collin-Smith, LJ; Daniels, AJ; Deaton, DN; Goetz, AS; Laudeman, CP; Littleton, TR; Musso, DL; Morgan, RJ; Szewczyk, JR; Zhang, C Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead. Bioorg Med Chem Lett 18: 5451-5 (2008)
- ChEMBL_738368 (CHEMBL1743445) Mechanism based inhibition of human cytochrome P450 3A4 measured by nifedipine oxidation, omeprazole 3-hydroxylation and omeprazole sulfoxydation
- ChEMBL_2065906 (CHEMBL4721159) Inhibition of human CYP2C19 using omeprazole as substrate
- ChEMBL_1435234 (CHEMBL3390680) Inhibition of CYP2C19 (unknown origin) using omeprazole substrate
- ChEMBL_1485705 (CHEMBL3541097) Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method
- ChEMBL_1705365 (CHEMBL4056598) Inhibition of CYP2C19 in human hepatocyte microsomes using omeprazole substrate by HPLC/MS/MS method
- ChEMBL_821318 (CHEMBL2040148) Inhibition of CYP2C19 in human liver microsomes using omeprazole as substrate by LC-MS/MS analysis
- ChEMBL_1833053 (CHEMBL4333061) Inhibition of CYP2C19 in human liver microsomes assessed as reduction in omeprazole hydroxylation by tandem mass spectrometry analysis
- ChEMBL_2188374 (CHEMBL5100456) Inhibition of CYP2C19 in human liver Microsome using omeprazole as substrate in presence of NADPH by LC-MS/MS analysis
- ChEMBL_2278022 Inhibition of CYP2C19 in human liver microsome suspension using omeprazole substrate incubated for 30 mins by LC/MS analysis
- ChEMBL_2089576 (CHEMBL4770839) Inhibition of CYP2C19 in human liver microsomes using omeprazole as substrate incubated for 5 mins followed by NADPH addition and measured after 20 mins by LC-MS/MS analysis
- ChEMBL_1735369 (CHEMBL4150905) Inhibition of CYP2C19 in human liver microsomes using omeprazole as substrate preincubated for 5 mins followed by addition of NADPH-regenerating system and measured after 15 mins by UPLC-MS analysis
- ChEMBL_2064947 (CHEMBL4720200) Inhibition of human liver microsome CYP2C19 using omeprazole as substrate incubated for 5 mins followed by NADPH addition and further incubated for 10 mins in shaking water bath by LC-MS/MS analysis
- ChEMBL_1781442 (CHEMBL4252959) Inhibition of CYP2C19 in human pooled human liver microsomes using omeprazole as substrate assessed as omepraozle hydroxylation preincubated for 5 mins followed by NADPH addition measured after 15 mins by LC-MS/MS analysis
- Optical Titration Assay Dissociation constants (Kd values) for binding of the substrates N-palmitoylglycine (NPG) and omeprazole (OMP) to WT and mutant BM3 heme domains were determined by UVvisible absorption titrations using ~1-4 μM protein in 100mMKPi, pH 7.0, at 25 °C (assay buffer) in 1-cm path length quartz cuvettes and as in our previous studies. Spectra were recorded for substrate-free enzymes and following addition of ligands during substrate titrations (typically 800 to 250 nm). Titrations were recorded until no further spectral changes were observed in the P450s.